Form 4: Schrodinger SVP & Controller Jenny Herman Reports Stock and Option Awards

Jenny Herman, SVP & Controller of Schrodinger, Inc., reports the acquisition of restricted stock units and stock options.

Summary

• On March 3, 2025, Jenny Herman, SVP & Controller of Schrodinger, Inc., was granted 9,800 restricted stock units (RSUs) and an option to purchase 8,400 shares of common stock.
• The RSUs will vest in equal installments on March 4 of 2026, 2027, 2028, and 2029, contingent upon continued service with the company.
• The stock options, with an exercise price of $21.24, vest 25% on March 3, 2026, and the remainder in equal monthly installments through March 3, 2029.
• Following these transactions, Herman directly owns 28,015 shares of common stock, including 21,113 unvested RSUs, and holds options for 8,400 shares.

Sentiment

Score: 7

Explanation: The document reflects standard executive compensation practices, indicating stability and alignment of interests. The sentiment is neutral to positive as it suggests confidence in the company's future.

Positives

• The grant of RSUs and stock options to a key executive like the SVP & Controller suggests an incentive alignment with the company's long-term performance.
• The vesting schedules for both RSUs and stock options encourage continued service and commitment from the executive.

Future Outlook

The document does not contain explicit forward-looking statements, but the vesting schedules of the RSUs and stock options suggest a multi-year commitment from the executive.

Industry Context

Equity compensation is a common practice in the technology and pharmaceutical industries to attract and retain talent, aligning executive interests with shareholder value.

Comparison to Industry Standards

• Stock option and RSU grants are standard compensation components for executives in publicly traded companies, particularly in the tech and biotech sectors.
• Vesting schedules of four years with annual or monthly vesting are typical to ensure long-term commitment.
• Companies like Moderna, BioNTech, and other similar firms often use similar equity compensation packages for their executives.

Stakeholder Impact

• Shareholders may view the equity grants as a positive sign, aligning management's interests with long-term company performance.
• Employees may see the grants as a reflection of the company's commitment to its leadership team.

Key Dates